 The initial target enrollment is 60 individuals in three group classifications healthy, asthmatic, immune-compromised e.g. Leukemia patients, with each group further subdivided into two age groups Young adults aged 18-25 or Older adults aged 55, without gender or ethnicity restrictions. 